Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/136120
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Mucin architecture behind the immune response: Design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment |
Autor: | Martínez-Sáez, N.; Supekar, N.T.; Wolfert, M.A.; Bermejo, I.A.; Hurtado-Guerrero, Ramón CSIC ORCID; Asensio, Juan Luis CSIC ORCID; Jiménez-Barbero, Jesús CSIC ORCID; Busto, J.H.; Avenoza, A.; Boons, G.J.; Peregrina, Jesús M.; Corzana, Francisco | Fecha de publicación: | 2016 | Editor: | Royal Society of Chemistry (UK) | Citación: | Chemical Science 7: 2294-2301 (2016) | Resumen: | A tripartite cancer vaccine candidate, containing a quaternary amino acid (α-methylserine) in the most immunogenic domain of MUC1, has been synthesized and examined for antigenic properties in transgenic mice. The vaccine which is glycosylated with GalNAc at the unnatural amino acid, was capable of eliciting potent antibody responses recognizing both glycosylated and unglycosylated tumour-associated MUC1 peptides and native MUC1 antigen present on cancer cells. The peptide backbone of the novel vaccine presents the bioactive conformation in solution and is more resistant to enzymatic degradation than the natural counter part. In spite of these features, the immune response elicited by the unnatural vaccine was not improved compared to a vaccine candidate containing natural threonine. These observations were rationalized by conformational studies, indicating that the presentation and dynamics of the sugar moiety displayed by the MUC1 derivative play a critical role in immune recognition. It is clear that engineered MUC1-based vaccines bearing unnatural amino acids have to be able to emulate the conformational properties of the glycosidic linkage between the GalNAc and the threonine residues. The results described here will be helpful to the rational design of efficacious cancer vaccines. | Versión del editor: | http://dx.doi.org/10.1039/c5sc04039f | URI: | http://hdl.handle.net/10261/136120 | DOI: | 10.1039/c5sc04039f | Identificadores: | doi: 10.1039/c5sc04039f issn: 2041-6520 e-issn: 2041-6539 |
Aparece en las colecciones: | (CIB) Artículos (IQOG) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
c5sc04039f.pdf | 1,28 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
13
checked on 21-mar-2024
SCOPUSTM
Citations
36
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
37
checked on 29-feb-2024
Page view(s)
271
checked on 22-abr-2024
Download(s)
268
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.